Motus GI Announces First Commercial Placements of Pure-Vu® System as part of U.S. Market Launch

“The Pure-Vu System allows us to complete colonoscopy procedures that would have otherwise been delayed or cancelled due to insufficient bowel prep. The positive impact the Pure-Vu System can have on quality patient care, coupled with a reduction in length of stay for inpatients is exciting,” said Sreeram Parupudi, M.D., Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine at The University of Texas Medical Branch (UTMB) in Galveston, Texas.

“Insufficient bowel prep is a universal issue that has consequences for both patients and providers, including costly extended hospitalizations. The Pure-Vu System’s enhanced workstation mobility and streamlined set-up makes utilizing the system simple and effective. Using Pure-Vu to control the inherent delays associated with poor bowel prep can result in significant savings for the hospital and potentially free up valuable inpatient beds sooner,” commented Brian C. Jacobson, MD, Associate Professor of Medicine, Boston University School of Medicine, Section of Gastroenterology, Boston Medical Center.

“This technology has given us a new way to improve visibility and bowel preparation scores during colonoscopies on hospitalized or poorly prepped patients,” said Dr. Peter Stanich, Assistant Professor of Gastroenterology, Hepatology and Nutrition at The Ohio State University Wexner Medical Center and College of Medicine.

“Execution of our commercial strategy for the Pure-Vu System continues to progress as planned and we are excited to have started placing our Pure-Vu System at targeted sites as part of the initial U.S. market launch,” said Tim Moran, Chief Executive Officer of Motus GI. “Feedback from physicians and their staff members has been overwhelmingly supportive.”

“The U.S. hospital inpatient colonoscopy market is comprised of approximately 1.5 million annual procedures, many of which can be delayed or cancelled. We believe the Pure-Vu System can reduce costs associated with delayed and repeat procedures, as well as extended hospitalization stays due to insufficient bowel prep. To support the methodical commercial roll-out of our Pure-Vu System, we continue to strengthen our sales organization with the addition of seasoned medical device sales professionals, strategically expanding our footprint and reach to key target hospital accounts that can become strong reference customers going forward,” concluded Mr. Moran.

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 26, 2019, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005489/en/